Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | SMO | Q99835 | 10/20 | 0.48 |
| ▸ | MTTP | P55157 | 11/20 | 0.44 |
| ▸ | APOB | P04114 | 10/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597683 | 0.89 | PPARA (0.49) | NR1H4PPARGPPARDPPARAMTTP | |
| SCHEMBL2597850 | 0.86 | PPARG (0.53) | NR1H4PPARGPPARDPPARAMTTP | |
| SCHEMBL3729050 | 0.84 | SMO (0.42) | NR1H4PPARGPPARDPPARASMO | |
| SCHEMBL14778306 | 0.84 | MTTP (0.47) | SMOMTTPAPOB | |
| SCHEMBL2597937 | 0.83 | PSEN1 (0.48) | NR1H4PPARGPPARDPPARAMTTP | |
| SCHEMBL2597817 | 0.81 | MTTP (0.44) | SMOMTTPAPOB | |
| SCHEMBL14777521 | 0.79 | SMO (0.39) | NR1H4PPARGPPARDPPARASMO | |
| SCHEMBL2597889 | 0.79 | SMO (0.41) | SMOMTTPAPOB | |
| SCHEMBL2597800 | 0.79 | SMO (0.41) | SMOMTTPAPOB | |
| SCHEMBL2597716 | 0.79 | PSEN1 (0.46) | NR1H4PPARGPPARDPPARAMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571860-A1 | 2-PHENYL BENZOYLAMIDES | Pfizer Inc (US) | 2013-03-27 | — | — | EP | claimed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | claimed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | claimed |
| EP-2571860-A1 | 2-PHENYL BENZOYLAMIDES | Pfizer Inc (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | APOB, MTTP, HADHB | NR1H4 248/4885PPARG 570/4885PPARD 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.